Significance of HER2 low-level copy gain in Barrett's cancer: Implications for fluorescence in situ hybridization testing in tissues

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 5115-5123

  Rauser, Sandra ^a,c   Weis, Roland ^b   Braselmann, Herbert ^a   Feith, Marcus ^c   Stein, Hubert J ^e   Langer, Rupert ^d   Hutzler, Peter ^a   Hausmann, Michael ^f   Lassmann, Silke ^b   Siewert, Jörg Rüdiger ^c   Höfler, Heinz ^a,d   Werner, Martin ^b   Walch, Axel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e University Hospital Salzburg   (Austria)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 17; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE NUMBER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; THREE DIMENSIONAL IMAGING; TISSUE MICROARRAY; ESOPHAGUS TUMOR; GENE DOSAGE; GENETICS; METHODOLOGY; PATHOLOGY; PROTO ONCOGENE;

AGED; BARRETT ESOPHAGUS; CHROMOSOMES, HUMAN, PAIR 17; ESOPHAGEAL NEOPLASMS; GENE DOSAGE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 34548835771     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0465     Document Type: Article

References (41)

1. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus, and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84.
2. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 2004;6:11-6.
3. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006;13:12-30.
4. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-52.
5. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999;26:108-16.
6. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
7. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
8. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005;36:250-61.
9. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
10. Hopman AH, van Hooren E, van de Kaa CA, Vooijs PG, Ramaekers FC. Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. Mod Pathol 1991;4:503-13.
11. Thompson CT, LeBoit PE, Nederlof PM, Gray JW. Thick-section fluorescence in situ hybridization on formalin-fixed, paraffin-embedded archival tissue provides a histogenetic profile. Am J Pathol 1994;144:237-43.
12. Aubele M, Zitzelsberger H, Szucs S, et al. Comparative FISH analysis of numerical chromosome 7 abnormalities in 5-micron and 15-micron paraffin-embedded tissue sections from prostatic carcinoma. Histochem Cell Biol 1997;107:121-6.
13. D'Alessandro I, Zitzelsberger H, Hutzler P, et al. Numerical aberrations of chromosome 7 detected in 15 microns paraffin-embedded tissue sections of primary cutaneous melanomas by fluorescence in situ hybridization and confocal laser scanning microscopy. J Cutan Pathol 1997;24:70-5.
14. Chin K, de Solorzano CO, Knowles D, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004;36:984-8.
15. Maierhofer C, Gangnus R, Diebold J, Speicher MR. Multicolor deconvolution microscopy of thick biological specimens. Am J Pathol 2003;162:373-9.
16. Wiech T, Timme S, Riede F, et al. Human archival tissues provide a valuable source for the analysis of spatial genome organization. Histochem Cell Biol 2005;123:229-38.
17. Werner M, Flejou JF, Hainaut P, et al. Adenocarcinoma of the oesophagus In World Health Organization Classification of Tumours. In: Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 20-6.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
19. Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT. Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem 2001;47:844-51.
20. Crockett DK, Lin Z, Vaughn CP, Lim MS, Elenitoba-Johnson KS. Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab Invest 2005;85:1405-15.
21. Walch A, Specht K, Bink K, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia- dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab Invest 2001;81:791-801.
22. Walch A, Bink K, Hutzler P, et al. Sequential multilocus fluorescence in situ hybridization can detect complex patterns of increased gene dosage at the single cell level in tissue sections. Lab Invest 2001;81:1457-9.
23. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
24. Persons DL, Tubbs RR, Cooley LD, et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 2006;130:325-31.
25. Koscielny S, Terrier P, Daver A, et al. Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. Eur J Cancer 1998;34:476-81.
26. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-8.
27. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-15.
28. Tovey S, Reeves J, Stanton P, Ozanne B, Bartlett J, Cooke T. Low expression of HER2 protein in breast cancer is biologically significant. J Pathol 2006;210:358-62.
29. Rimm DL. What brown cannot do for you. Nat Biotechnol 2006;24:914-6.
30. Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9.
31. Rossi E, Villanacci V, Bassotti G, et al. Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol 2006;15:125-30.
32. Walch A, Specht K, Braselmann H, et al. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer 2004;112:747-53.
33. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
34. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35-9.
35. Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and cerbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6:290-7.
36. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol 1995;48:129-32.
37. Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994;73:1785-94.
38. Flejou JF, Paraf F, Muzeau F, et al. Expression of cerbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994;47:23-6.
39. Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-9.
40. Jankowski J, Coghill G, Hopwood D, Wormsley KG. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992;33:1033-8.
41. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005;29:1221-7.